Fast triage of chest pain patients

ADVIA Centaur High-Sensitivity Troponin I Assay

The ADVIA Centaur® High-Sensitivity Troponin I (TNIH) assay* is the latest addition to Siemens Healthineers’ comprehensive cardiac menu to assist clinicians with the diagnosis and treatment of chest pain patients. Designed to aid in diagnosing acute myocardial infarctions (AMI) through the quantitative measurement of cardiac troponin I in serum or plasma, high-sensitivity troponin plays a critical role in the timely diagnosis of AMI, or heart attacks.

ADVIA Centaur High-Sensitivity Troponin I assay – Accurate results you can...
ADVIA Centaur High-Sensitivity Troponin I assay – Accurate results you can trust for fast triage of chest pain patients.
Source: Siemens Healthineers
The ADVIA Centaur High-Sensitivity Troponin I assay.
The ADVIA Centaur High-Sensitivity Troponin I assay.
Source: Siemens Healthineers

The ADVIA Centaur® High-Sensitivity Troponin I (TNIH) assay* is the latest addition to Siemens Healthineers’ comprehensive cardiac menu to assist clinicians with the diagnosis and treatment of chest pain patients. Designed to aid in diagnosing acute myocardial infarctions (AMI) through the quantitative measurement of cardiac troponin I in serum or plasma, high-sensitivity troponin plays a critical role in the timely diagnosis of AMI, or heart attacks.

The ADVIA Centaur® High-Sensitivity Troponin I assay is a true high-sensitivity assay:

  • Offers improved cardiac patient care with a high-sensitivity troponin assay that meets current European Society of Cardiology clinical guidelines
  • Provides fast, accurate and actionable test results allow clinicians to confidently rule in/rule out a myocardial infarction when triaging patients with chest pain
  • Ensures reliable results from a proven, trusted technology coupled with three new monoclonal antibodies

Compared to traditional troponin assays, the Siemens Healthineers ADVIA Centaur TNIH assay is able to detect lower levels of troponin and smaller changes to a patient’s troponin levels, which may be an early indication of AMI. This design affords clinicians greater confidence in patient results at the low end of the assay range by delivering precision that provides the ability to measure slight, yet critical, changes between serial troponin I values.

Precision at the low end is important to minimize analytic variation that could confuse a clinician’s assessment of a clinically significant change. With this data in hand, clinicians have the ability to more quickly diagnose and treat patients with suspected AMI, in some cases in as little as one to three hours.

Click here to learn more

*Not available for sale in the U.S.

 

Source: Siemens Healthineers

01.07.2017

Read all latest stories

Related articles

Photo

Coronavirus countermeasures

Learning from China – the role of radiology in combatting COVID-19

As the first country to be hit by COVID-19, China learned a number of early lessons into how to combat the highly-infectious disease. With radiology teams playing an important role and utilising CT…

Photo

Siemens Healthineers at RSNA 2019

Join us as we enter the era of intelligent CT imaging

Curious about how intelligent imaging can work with you in CT? Then join us at this year’s RSNA, North Hall, Booth #7530, where you can experience our new Somatom X.cite and myExam Companion.

Photo

Digitalization

Healthcare: confidence in cloud computing grows

Consider the diagnostic and therapeutic possibilities resulting from access to pertinent data from thousands of anonymized patient medical scans. What new patterns, options, or evidence for…

Related products